Literature DB >> 32722778

High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study.

Elisabeth Schorb1, Benjamin Kasenda2, Gabriele Ihorst1,3, Florian Scherer1, Julia Wendler4, Lisa Isbell1, Heidi Fricker1, Juergen Finke1, Gerald Illerhaus4.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32722778      PMCID： PMC7391148          DOI： 10.1182/bloodadvances.2020002064

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  25 in total

1.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

2.  Treatment for primary CNS lymphoma: the next step.

Authors:  L E Abrey; J Yahalom; L M DeAngelis
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

3.  Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  K Hoang-Xuan; L Taillandier; O Chinot; P Soubeyran; U Bogdhan; J Hildebrand; M Frenay; N De Beule; J Y Delattre; B Baron
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

4.  Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly.

Authors:  Antonio M P Omuro; Luc Taillandier; Olivier Chinot; Charlotte Carnin; Maryline Barrie; Khe Hoang-Xuan
Journal:  J Neurooncol       Date:  2007-09-21       Impact factor: 4.130

5.  A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.

Authors:  Gaelle Olivier; Aline Clavert; Laurence Lacotte-Thierry; Martine Gardembas; Martine Escoffre-Barbe; Annie Brion; Isabelle Cumin; Eric Legouffe; Philippe Solal-Celigny; Michèle Chabin; Pierre Ingrand; Philippe Colombat; Vincent Delwail
Journal:  Am J Hematol       Date:  2014-08-27       Impact factor: 10.047

6.  Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).

Authors:  H Ghesquières; C Ferlay; C Sebban; D Perol; A Bosly; O Casasnovas; O Reman; B Coiffier; H Tilly; P Morel; E Van den Neste; P Colin; C Haioun; P Biron; J-Y Blay
Journal:  Ann Oncol       Date:  2009-11-13       Impact factor: 32.976

7.  High-dose methotrexate for elderly patients with primary CNS lymphoma.

Authors:  Jay-Jiguang Zhu; Elizabeth R Gerstner; David A Engler; Maciej M Mrugala; Whitney Nugent; Kristin Nierenberg; Fred H Hochberg; Rebecca A Betensky; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2008-08-29       Impact factor: 12.300

8.  High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).

Authors:  K Fritsch; B Kasenda; E Schorb; P Hau; J Bloehdorn; R Möhle; S Löw; M Binder; J Atta; U Keller; H-H Wolf; S W Krause; G Heß; R Naumann; S Sasse; C Hirt; M Lamprecht; U Martens; A Morgner; J Panse; N Frickhofen; A Röth; C Hader; M Deckert; H Fricker; G Ihorst; J Finke; G Illerhaus
Journal:  Leukemia       Date:  2016-11-15       Impact factor: 11.528

9.  Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.

Authors:  Elisabeth Schorb; Juergen Finke; Gabriele Ihorst; Benjamin Kasenda; Heidi Fricker; Gerald Illerhaus
Journal:  BMC Cancer       Date:  2019-03-29       Impact factor: 4.430

10.  Trends in primary central nervous system lymphoma incidence and survival in the U.S.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Caroline Besson; Christina A Clarke; Lindsay M Morton; Leticia Nogueira; Karen Pawlish; Elizabeth L Yanik; Gita Suneja; Eric A Engels
Journal:  Br J Haematol       Date:  2016-03-28       Impact factor: 8.615
View more
  8 in total

Review 1.  Treatment Options for Recurrent Primary CNS Lymphoma.

Authors:  Leon D Kaulen; Joachim M Baehring
Journal:  Curr Treat Options Oncol       Date:  2022-10-07

2.  High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity.

Authors:  Sabine Seidel; Verena Nilius-Eliliwi; Thomas Kowalski; Deepak Ben Vangala; Uwe Schlegel; Roland Schroers
Journal:  Cancers (Basel)       Date:  2022-04-23       Impact factor: 6.575

3.  Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Authors:  Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 31.777

Review 4.  Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity.

Authors:  Kun-Wei Song; Tracy Batchelor
Journal:  Curr Oncol Rep       Date:  2021-09-15       Impact factor: 5.075

5.  A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.

Authors:  Yutaro Suzuki; Naoto Imoto; Shunichi Ishihara; Shinji Fujiwara; Rie Ito; Toshiyasu Sakai; Satomi Yamamoto; Isamu Sugiura; Shingo Kurahashi
Journal:  Intern Med       Date:  2021-10-19       Impact factor: 1.282

6.  Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.

Authors:  Lauren R Schaff; Prakash Ambady; Nancy D Doolittle; Christian Grommes
Journal:  Ann Lymphoma       Date:  2021-03

7.  Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis.

Authors:  Jing Liu; Jiayuan Guo; Xuefei Sun; Yuanbo Liu; Chunji Gao
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

8.  Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.

Authors:  Julia Wendler; Christopher P Fox; Elisabeth Schorb; Gerald Illerhaus; Elke Valk; Cora Steinheber; Heidi Fricker; Lisa K Isbell; Simone Neumaier; Jessica Okosun; Florian Scherer; Gabriele Ihorst; Kate Cwynarski
Journal:  BMC Cancer       Date:  2022-09-10       Impact factor: 4.638
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.